Randomized Trial of Platelet-Transfusion Thresholds in Neonates

Anna Curley(John Radcliffe Hospital), Simon Stanworth(John Radcliffe Hospital), Karen A. Willoughby(NHS Blood and Transplant), Susanna F. Fustolo‐Gunnink(Leiden University Medical Center), Vidheya Venkatesh(John Radcliffe Hospital), Cara Hudson(NHS Blood and Transplant), Alison Deary(NHS Blood and Transplant), Renate Hodge(NHS Blood and Transplant), Valerie Hopkins(NHS Blood and Transplant), Beatriz Lopez Santamaria(Guy's and St Thomas' NHS Foundation Trust), Ana Sabrina Mora(NHS Blood and Transplant), Charlotte Llewelyn(NHS Blood and Transplant), Angela D’Amore(John Radcliffe Hospital), Rizwan Khan(John Radcliffe Hospital), Wes Onland(John Radcliffe Hospital), Enrico Lopriore(John Radcliffe Hospital), Karin Fijnvandraat(Leiden University Medical Center), Helen New(NHS Blood and Transplant), Paul Clarke(University of East Anglia), Timothy J. Watts(Guy's and St Thomas' NHS Foundation Trust)
New England Journal of Medicine
November 2, 2018
Cited by 429Open Access
Full Text

Abstract

BACKGROUND: Platelet transfusions are commonly used to prevent bleeding in preterm infants with thrombocytopenia. Data are lacking to provide guidance regarding thresholds for prophylactic platelet transfusions in preterm neonates with severe thrombocytopenia. METHODS: In this multicenter trial, we randomly assigned infants born at less than 34 weeks of gestation in whom severe thrombocytopenia developed to receive a platelet transfusion at platelet-count thresholds of 50,000 per cubic millimeter (high-threshold group) or 25,000 per cubic millimeter (low-threshold group). Bleeding was documented prospectively with the use of a validated bleeding-assessment tool. The primary outcome was death or new major bleeding within 28 days after randomization. RESULTS: A total of 660 infants (median birth weight, 740 g; and median gestational age, 26.6 weeks) underwent randomization. In the high-threshold group, 90% of the infants (296 of 328 infants) received at least one platelet transfusion, as compared with 53% (177 of 331 infants) in the low-threshold group. A new major bleeding episode or death occurred in 26% of the infants (85 of 324) in the high-threshold group and in 19% (61 of 329) in the low-threshold group (odds ratio, 1.57; 95% confidence interval [CI], 1.06 to 2.32; P=0.02). There was no significant difference between the groups with respect to rates of serious adverse events (25% in the high-threshold group and 22% in the low-threshold group; odds ratio, 1.14; 95% CI, 0.78 to 1.67). CONCLUSIONS: Among preterm infants with severe thrombocytopenia, those randomly assigned to receive platelet transfusions at a platelet-count threshold of 50,000 per cubic millimeter had a significantly higher rate of death or major bleeding within 28 days after randomization than those who received platelet transfusions at a platelet-count threshold of 25,000 per cubic millimeter. (Funded by the National Health Service Blood and Transplant Research and Development Committee and others; Current Controlled Trials number, ISRCTN87736839 .).


Related Papers

No related papers found

Powered by citation graph analysis